RESUMO
Objective:To study the effect of pidotimod combined with montelukast sodium in the treatment of patients with asthma, and its influence on the levels of inflammatory factors and immune function.Methods:From February 2019 to February 2020, 102 patients with bronchial asthma admitted to Zhuji People's Hospital were randomly divided into the observation group and the control group, with 51 cases in each group.The control group was treated with montelukast sodium, and the observation group was given pidotimod combined with montelukast sodium.The clinical effect, lung function index, inflammatory factors, T lymphocyte subsets and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 90.20%(46/51), which was higher than that of the control group [74.51%(38/51)](χ 2=4.317, P=0.038). After treatment, FEV 1, FVC, PEF in the observation group were (82.89±6.94)%, (3.89±0.45)L, (3.49±0.49)L/s, respectively, which were higher than those in the control group [(77.89±6.79)%, (3.58±0.43)L, (3.21±0.45)L/s] ( t=7.370, 5.753, 4.239, all P<0.05). After treatment, the serum levels of procalcitonin (PCT), interleukin-6 (IL-6), C-reactive protein (CRP) in the observation group were (1.45±0.49)μg/L, (9.87±2.65)mg/L, (5.79±1.48)mg/L, respectively, which were lower than those in the control group [(1.79±0.55)μg/L, (12.34±2.97)mg/L, (7.23±1.68)mg/L] ( t=4.624, 6.542, 8.090, all P<0.05). After treatment, the CD 3+ , CD 4+ , CD 4+ /CD 8+ in the observation group were (53.43±5.43)%, (46.34±5.31)%, (1.54±0.23), respectively, which were higher than those in the control group [(48.09±5.17)%, (41.89±5.15)%, (1.26±0.22)], while the CD 8+ in the observation group[(30.65±3.54)%] was lower than that in the control group[(33.72±3.69)%], the differences were statistically significant ( t=3.901, 4.080, 4.072, 5.967, all P<0.05). During the treatment period, the incidences of adverse reactions in the observation group and the control group were 15.69%(8/51) and 9.80%(5/51), respectively, there was no statistically significant difference between the two groups (χ 2=0.793, P=0.373). Conclusion:Pidotimod combined with montelukast sodium has significant therapeutic effect on bronchial asthma.It can improve the pulmonary function, reduce the levels of inflammatory factors, improve the immune function of the body, and has good therapeutic safety.It has a high clinical application value.
RESUMO
Objective To explore the influence of Montelukast in the treatment of patients with bronchial asthma on the immune response,and to provide the basis for clinical treatment.Methods 104 patients with bronchial asthma were selected.They were randomly divided into the treatment group and the control group by the random number table method,with 52 cases in each group.The control group patients were given conventional treatment,and the treatment group were treated with Montelukast on the basis of the control group.Daytime symptom and night symptom of the two groups before and after treatment were assessed,and airway reactivity by the early respiratory resistance (Rrsc)and response threshold (Dmin)were evaluated.And the change of T lymphocyte subsets before and after the treatment were detected.Results The day symptom scores,night symptom scores and Rrsc of the treatment group after treatment were respectively (0.49 ±0.12)points,(0.66 ±0.20)points and (2.19 ±0.38)cmH2 O,which were lower than those of the control group after treatment(t =7.90,8.13,8.24,all P <0.05).The data of the two groups after treatment were lower than those before treatment,the differences were statistically significant (t =9.38,8.66, 9.17,9.41,8.90,9.24,all P <0.05).Dmin of the treatment group after treatment was (8.29 ±0.44)U,which was higher than that of the control group after treatment,the data of the two groups after treatment were higher than those before the treatment,the differences were statistically significant(t =7.41,8.23,all P <0.05).CD +4 and CD +4 /CD +8 of the treatment group after treatment were (43.03 ±5.02)% and(1.79 ±0.34),respectively,which were higher than those of the control group after treatment (t =9.81,10.04,all P <0.05 ).The data of the two groups after treatment were higher than those before the treatment,the differences were statistically significantly different (t =10.62,10.33,10.93,10.62,all P <0.05).CD +8 of the treatment group after treatment was (23.38 ±3.88)%, which was lower than that of the control group after treatment(t =9.93,P <0.05),the data of the two groups after treatment were lower than those before treatment,the differences were statistically significant (t =9.16,9.29,all P <0.05 ).Conclusion Montelukast treatment of bronchial asthma can significantly improve symptoms and immune function of patients,it is worthy of clinical popularization and application.